argenx SE (ARGX) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

$478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo...

argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024

July 18, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent...

Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent...

argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse...

argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024

R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and...

argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

argenx Reports First Quarter 2024 Financial Results and Provides Business Update

$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]